# A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

> **NCT04153929** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 413 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BI 456906
- **DRUG:** Placebo
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT04153929
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-30
- **Primary completion:** 2021-10-08
- **Final completion:** 2021-11-04
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04153929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04153929, "A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04153929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*